cetuximab + motolimod + nivolumab

Cetuximab + motolimod + nivolumab is an investigational combination of three distinct agents with complementary mechanisms. Cetuximab is an epidermal growth factor receptor (EGFR)–targeting monoclonal antibody that inhibits tumor growth and promotes antibody-dependent cellular cytotoxicity. Motolimod is a small molecule agonist of toll-like receptor 8 (TLR8), designed to activate innate and adaptive immune responses including enhancement of dendritic cell activation and cytokine production. Nivolumab is a monoclonal antibody that blocks the programmed death-1 (PD-1) checkpoint, restoring T-cell antitumor activity. This combination aims to maximize antitumor immunity by concurrently blocking tumor cell signaling (EGFR), stimulating innate immune activation (TLR8), and releasing T-cell mediated immune suppression (PD-1). This regimen has been investigated primarily in head and neck squamous cell carcinoma; the specific triplet (cetuximab + motolimod + nivolumab) remains experimental, though each component is individually approved for various indications.[1][3][5][7]

Other names

VTX-2337 + cetuximab + nivolumabmotolimod + cetuximab